Michael Ackermann, vice president of neurostimulation at the pharmaceutical giant Allergan, offers thoughts on how healthcare policy will be affected by the election of Donald Trump as America’s commander in chief. On the day after Trump was elected president, Ackermann discussed how much is unknown about the new administration and its agenda, how another system for encouraging Americans to get insured may replace the Affordable Care Act if it is dismantled, and how soaring healthcare costs will remain a major issue.
